World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   412 records for 97 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4 5 6 7 8 9 10
Recruitment statusMain ID Public TitleDate of Registration
AuthorisedEUCTR2013-004392-12-SI
Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetes 13/02/2014
RecruitingISRCTN21662248
Complete versus culprit-only revascularization strategies to treat multi-vessel disease after primary percutaneous coronary interventions (PCI) for ST-segment elevation myocardial infarction
16/01/2014
AuthorisedEUCTR2013-000013-20-SI
A trial investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of long-acting growth hormone compared to daily dosing of Norditropin® SimpleXx® in children with growth hormone deficiency 20/09/2013
AuthorisedEUCTR2012-000452-34-DK
Prediction and prevention of kidney disease in patients with diabetes 18/09/2013
RecruitingCTRI/2013/09/003977
A Phase 3 Study of Epoetin Alfa plus Standard Supportive Care versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
12-09-2013
Not RecruitingEUCTR2010-022134-89-HU
Efficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2010-022134-89-SIEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.15/11/2013
AuthorisedEUCTR2010-022134-89-ESEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.01/10/2013
AuthorisedEUCTR2010-022134-89-CZEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.17/10/2013
AuthorisedEUCTR2010-022134-89-ITEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.20/09/2013
Not RecruitingEUCTR2010-022134-89-NLEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.04/10/2013
Not RecruitingEUCTR2010-022134-89-EEEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.14/10/2013
Not RecruitingEUCTR2010-022134-89-LTEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.24/10/2013
Not RecruitingEUCTR2010-022134-89-DKEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.23/01/2014
AuthorisedEUCTR2010-022134-89-ATEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.03/02/2014
AuthorisedEUCTR2010-022134-89-HREfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.29/08/2014
11/09/2013
AuthorisedEUCTR2013-001999-38-BE
A clinical study to test the efficacy of a new product (TNF-Kinoid) in patients with Rheumatoid Arthritis in whom treatment with methotrexate is not working anymore 11/07/2013
AuthorisedEUCTR2013-000087-29-IT
International study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2013-000087-29-FIInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.30/07/2013
AuthorisedEUCTR2013-000087-29-SIInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.03/09/2013
AuthorisedEUCTR2013-000087-29-LVInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.02/09/2013
AuthorisedEUCTR2013-000087-29-EEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.10/10/2013
AuthorisedEUCTR2013-000087-29-GRInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.21/10/2013
AuthorisedEUCTR2013-000087-29-ESInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.12/07/2013
AuthorisedEUCTR2013-000087-29-SEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.29/10/2013
AuthorisedEUCTR2013-000087-29-DEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.08/07/2013
AuthorisedEUCTR2013-000087-29-LTInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.28/01/2014
AuthorisedEUCTR2013-000087-29-PLInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.04/11/2013
AuthorisedEUCTR2013-000087-29-BEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.13/01/2014
RecruitingNCT01905943A Safety Study of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia19/07/2013
02/07/2013
AuthorisedEUCTR2012-003138-17-AT
Clinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2012-003138-17-PTClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer04/06/2013
AuthorisedEUCTR2012-003138-17-GRClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer25/06/2013
Not RecruitingEUCTR2012-003138-17-FIClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer20/05/2013
AuthorisedEUCTR2012-003138-17-ESClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer16/05/2013
AuthorisedEUCTR2012-003138-17-ITClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer03/05/2013
AuthorisedEUCTR2012-003138-17-IEClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer03/05/2013
AuthorisedEUCTR2012-003138-17-BGA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer10/06/2013
AuthorisedEUCTR2012-003138-17-GBA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer08/05/2013
AuthorisedEUCTR2012-003138-17-SEClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer30/05/2013
AuthorisedEUCTR2012-003138-17-EEA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer08/05/2013
AuthorisedEUCTR2012-003138-17-LVA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer10/05/2013
RecruitingNCT01860638A Comparison of Continuous Avastin (Bevacizumab) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Patients With Glioblastoma21/05/2013
24/04/2013
Not recruitingNCT01835431
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus 16/04/2013
    
1 2 3 4 5 6 7 8 9 10
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.2 - Version history